Medical devices, healthcare technology and the business of care
510(k) clearance · K260190

ARTHUR

ROPCA ApS · Decision date Jun 18, 2026

FDA DECISIONK260190

What did the FDA decide?

FDA records K260190 as a 510(k) premarket notification, with a decision dated Jun 18, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Jun 18, 2026

FDA source record

Regulatory record facts

Identifier
K260190
Regulatory pathway
510(k) premarket notification
Applicant
ROPCA ApS
Product code
IYO
Decision code
SESE
Decision date
Jun 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Imaging, Pulsed Echo, Ultrasonic.

Applicant
ROPCA ApS
Product code
IYO
FDA device class
2

FDA decision timeline

  1. K260190 received

    Application receipt date recorded by FDA.

  2. K260190 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code IYO

Product / regulatory recordCompanyPathwayDecision dateSource
Evident Vascular, Inc.510(k) clearanceOct 28, 2026FDA
Accuro XVK262093
Rivanna Medical, Inc.510(k) clearanceOct 20, 2026FDA
Lilium Otsuka Co., Ltd.510(k) clearanceOct 16, 2026FDA
MEDA Co., Ltd.510(k) clearanceSep 24, 2026FDA
Accuro 3SK253452
Rivanna Medical, Inc.510(k) clearanceJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ROPCA ApS

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Odense M

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records